ReactWise has secured £2.5 million in pre-seed funding, including a competitive Innovate UK grant, to enable AI-driven robotic laboratories and speed up pharmaceutical manufacturing R&D. The pre-seed round was backed by Y Combinator, the UK government, and leading venture capitalists and angel investors committed to advancing AI-driven, sustainable pharmaceutical manufacturing.
The discovery of novel pharmaceuticals is one of our most important weapons in fighting disease. However, the drug development pipeline is often driven by trial-and-error and held up for many months during the identification of scalable manufacturing processes, delaying clinical trials.
Since completing Y Combinator’s summer 2024 batch, ReactWise has launched their improved software and is currently running 12 pilot studies with some of the largest pharmaceutical companies. Moreover, in their robotic laboratory they have already screened thousands of chemical reactions to build up their proprietary reactivity models. By integrating with automated lab infrastructure and electronic lab notebooks, ReactWise is positioning itself as the next-generation intelligence layer for pharmaceutical R&D.
With growing demand for more efficient, cost-effective, and environmentally friendly manufacturing solutions, ReactWise is set to become a critical enabler for the pharmaceutical industry.
